Buchumschlag

Systemtherapie des Ovarialkarzinoms bei einem Rezidiv: Teil 2 : Leitthema

Vascular endothelial growth factor A (VEGF-A) is crucial for tumor progression in ovarian cancer and plays a key role in the development of malignant ascites. The rationale for therapeutically inhibiting angiogenesis is therefore obvious. By binding to VEGF, bevacizumab neutralizes its biological ac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Marmé, Frederik (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Deutsch
Veröffentlicht: August 2025
In: Die Onkologie
Year: 2025, Jahrgang: 31, Heft: 8, Pages: 787-799
ISSN:2731-7234
DOI:10.1007/s00761-025-01765-6
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00761-025-01765-6
Verlag, lizenzpflichtig, Volltext: http://link.springer.com/article/10.1007/s00761-025-01765-6
Volltext
Verfasserangaben:Frederik Marmé

MARC

LEADER 00000caa a2200000 c 4500
001 1935605569
003 DE-627
005 20250915113134.0
007 cr uuu---uuuuu
008 250911s2025 xx |||||o 00| ||ger c
024 7 |a 10.1007/s00761-025-01765-6  |2 doi 
035 |a (DE-627)1935605569 
035 |a (DE-599)KXP1935605569 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a ger 
084 |a 33  |2 sdnb 
100 1 |a Marmé, Frederik  |d 1974-  |e VerfasserIn  |0 (DE-588)132561972  |0 (DE-627)52394893X  |0 (DE-576)299226549  |4 aut 
245 1 0 |a Systemtherapie des Ovarialkarzinoms bei einem Rezidiv  |b Teil 2 : Leitthema  |c Frederik Marmé 
246 1 |i Englischsprachige Zusammenfassung unter dem Titel  |a Systemic treatment of recurrent ovarian cancer. Part 2 
264 1 |c August 2025 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online publiziert: 17. Juli 2025 
500 |a Gesehen am 11.09.2025 
520 |a Vascular endothelial growth factor A (VEGF-A) is crucial for tumor progression in ovarian cancer and plays a key role in the development of malignant ascites. The rationale for therapeutically inhibiting angiogenesis is therefore obvious. By binding to VEGF, bevacizumab neutralizes its biological activity. This decreases tumor vascularization and, thus, inhibits tumor growth. Results from two randomized phase III trials are available for patients with platinum-sensitive recurrence. In these studies, bevacizumab plus platinum-containing combination chemotherapy and the subsequent administration of bevacizumab maintenance therapy were investigated in comparison to chemotherapy alone. The result of both studies was a significant increase in progression-free survival (PFS) in favor of the bevacizumab combination. Based on these results, bevacizumab was approved in Europe for use in combination with carboplatin/gemcitabine and carboplatin/paclitaxel. A study also showed a significant difference in PFS in patients with relapse for whom platinum is not a suitable treatment option. The European Medicines Agency (EMA) has therefore approved bevacizumab in combination with paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan. The efficacy of platinum-free monochemotherapy in combination with bevacizumab in platinum-resistant relapse was confirmed in a further study. In addition to clinical development of new antibody-drug conjugates, new targeted treatment approaches and treatment with poly(ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors are also presented. 
546 |a Sprache der Zusammenfassungen: Deutsch und Englisch 
773 0 8 |i Enthalten in  |t Die Onkologie  |d Berlin : Springer Medizin, 2022  |g 31(2025), 8 vom: Aug., Seite 787-799  |h Online-Ressource  |w (DE-627)1805500619  |w (DE-600)3120761-3  |x 2731-7234  |7 nnas  |a Systemtherapie des Ovarialkarzinoms bei einem Rezidiv Teil 2 : Leitthema 
773 1 8 |g volume:31  |g year:2025  |g number:8  |g month:08  |g pages:787-799  |g extent:13  |a Systemtherapie des Ovarialkarzinoms bei einem Rezidiv Teil 2 : Leitthema 
856 4 0 |u https://doi.org/10.1007/s00761-025-01765-6  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://link.springer.com/article/10.1007/s00761-025-01765-6  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20250911 
993 |a Article 
994 |a 2025 
998 |g 132561972  |a Marmé, Frederik  |m 132561972:Marmé, Frederik  |d 60000  |d 61300  |d 50000  |e 60000PM132561972  |e 61300PM132561972  |e 50000PM132561972  |k 0/60000/  |k 1/60000/61300/  |k 0/50000/  |p 1  |x j  |y j 
999 |a KXP-PPN1935605569  |e 477091296X 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1935605569"],"doi":["10.1007/s00761-025-01765-6"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"language":["ger"],"disp":"Systemtherapie des Ovarialkarzinoms bei einem Rezidiv Teil 2 : LeitthemaDie Onkologie","recId":"1805500619","pubHistory":["Volume 28, Issue 5, (May 2022) -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Die Onkologie","subtitle":"Organ der Deutschen Krebsgesellschaft e.V.","title_sort":"Onkologie"}],"origin":[{"publisher":"Springer Medizin","dateIssuedDisp":"[May 2022]-","publisherPlace":"Berlin ; Heidelberg ; New York"}],"note":["Gesehen am 01.06.22"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["3120761-3"],"issn":["2731-7234"],"eki":["1805500619"]},"part":{"year":"2025","pages":"787-799","volume":"31","text":"31(2025), 8 vom: Aug., Seite 787-799","extent":"13","issue":"8"}}],"note":["Online publiziert: 17. Juli 2025","Gesehen am 11.09.2025"],"recId":"1935605569","name":{"displayForm":["Frederik Marmé"]},"origin":[{"dateIssuedDisp":"August 2025","dateIssuedKey":"2025"}],"person":[{"given":"Frederik","display":"Marmé, Frederik","family":"Marmé","role":"aut"}],"titleAlt":[{"title":"Systemic treatment of recurrent ovarian cancer. Part 2"}],"language":["ger"],"title":[{"title":"Systemtherapie des Ovarialkarzinoms bei einem Rezidiv","subtitle":"Teil 2 : Leitthema","title_sort":"Systemtherapie des Ovarialkarzinoms bei einem Rezidiv"}]} 
SRT |a MARMEFREDESYSTEMTHER2025 

Ähnliche Einträge